BNT162b2 Covid-19 Vaccine over 6 Months of Follow-up

When the BNT162b2 mRNA Covid-19 vaccine was authorized in the United States in late 2020, only 2 months of clinical trial data were available. Longer-term safety and efficacy data are needed. New research findings are summarized in a short video. https://www.facebook.com/watch/?v=1756665204528672&extid=WA-UNK-UNK-UNK-AN_GK0T-GK1C&ref=sharing Créditos: Comité científico Covid